| Name | Title | Contact Details |
|---|
The Cook County Health and Hospitals Systems mission is to deliver integrated health services with dignity and respect regardless of a patients ability to pay; foster partnerships with other health providers and communities to enhance the health of the public; and advocate for policies that promote the physical, mental and social well being of the people of Cook County. CCHHS is comprised of two hospitals, John H. Stroger, Jr. Hospital and Provident Hospital, a robust network of more than a dozen community health centers, the Ruth M. Rothstein CORE Center, the Cook County Department of Public Health, Cermak Health Services, which provides health care to individuals at the Cook County Jail and the Juvenile Temporary Detention Center, and CountyCare, a Medicaid managed care health plan. The system cares for more than 300,000 patients each year and its physicians are experts in their fields, committed to providing their patients with comprehensive, compassionate and cutting-edge care. Today, CCHHS is transforming the provision of health care in Cook County by promoting community-based primary and preventive care, growing an innovative, collaborative health plan and enhancing the patient experience.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body.
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.
We re committed to breakthrough firsts in womens sexual health. Novel ideas fuel our entrepreneurial passion. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we re trying to collectively accomplish.
Boston Microfluidics (BMF) is dedicated to connecting people to their health by increasing access to diagnostic testing for all people. Our technology is a unique combination of elegant sample processing solutions with an intuitive user interface. We strive to streamline current testing systems with devices that perform complex sample processing steps without the need for trained professionals or specialized laboratory equipment. We also seek to simplify diagnostic tests so that they can be used efficiently at the point of care, or even be available for direct sale to consumers. Above all, BMF works to help provide patients with the information they need to make choices about their health.